Radioiodine therapy of benign non-toxic goitre. Potential role of recombinant human TSH;Traitement radio-isotopique des goitres bénins non toxiques. Rôle potentiel de la TSH recombinante

Annales d'Endocrinologie

Volumn 72, Issue 2, 2011, Pages 129-135

  Fast, S ^a   Bonnema, S J ^a   Hegedus L ^a  

^a ODENSE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Goitre; MRrh TSH; Radioiodine therapy; Recombinant human thyrotropin; Rh TSH; Thyroid hormones

Indexed keywords

IODINE 131; LEVOTHYROXINE; PLACEBO; RECOMBINANT THYROTROPIN; THYROID HORMONE; THYROTROPIN;

ACUTE DISEASE; ACUTE THYROID SWELLING; ARTICLE; DECOMPRESSION; DISEASE SEVERITY; DOSE RESPONSE; DRUG ABSORPTION; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; DRUG UPTAKE; FEASIBILITY STUDY; HUMAN; HYPERTHYROIDISM; HYPOTHYROIDISM; NODULAR GOITER; PATIENT SATISFACTION; QUALITATIVE ANALYSIS; RADIATION CARCINOGENESIS; RADIATION DOSE; RADIATION HAZARD; RADIOACTIVITY; SYMPTOM; THYROID DISEASE; THYROIDECTOMY; THYROTROPIN BLOOD LEVEL; TREATMENT RESPONSE;

GOITER, NODULAR; HUMANS; IODINE RADIOISOTOPES; NEOPLASMS, RADIATION-INDUCED; RECOMBINANT PROTEINS; THYROID HORMONES; THYROTROPIN;

EID: 79955704719     PISSN: 00034266     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ando.2011.03.018     Document Type: Article

References (48)

1. Hegedus L., Hansen B.M., Knudsen N., Hansen J.M. Reduction of size of thyroid with radioactive iodine in multinodular non-toxic goitre. Br Med J 1988, 297(6649):661-662.
2. Nygaard B., Hegedus L., Gervil M., Hjalgrim H., Soe-Jensen P., Hansen J.M. Radioiodine treatment of multinodular non-toxic goitre. Br Med J 1993, 307(6908):828-832.
3. LeMoli R., Wesche M.F., Tiel-Van Buul M.M., Wiersinga W.M. Determinants of long-term outcome of radioiodine therapy of sporadic non-toxic goitre. Clin Endocrinol (Oxf) 1999, 50(6):783-789.
4. Wesche M.F., Tiel V., Lips P., Smits N.J., Wiersinga W.M. A randomized trial comparing levothyroxine with radioactive iodine in the treatment of sporadic non-toxic goiter. J Clin Endocrinol Metab 2001, 86(3):998-1005.
5. Bonnema S.J., Bertelsen H., Mortensen J., et al. The feasibility of high dose iodine 131 treatment as an alternative to surgery in patients with a very large goiter: effect on thyroid function and size and pulmonary function. J Clin Endocrinol Metab 1999, 84(10):3636-3641.
6. de Klerk J.M., van Isselt J.W., van D.A., et al. Iodine-131 therapy in sporadic non-toxic goiter. J Nucl Med 1997, 38(3):372-376.
7. Huysmans D.A., Hermus A.R., Corstens F.H., Barentsz J.O., Kloppenborg P.W. Large, compressive goiters treated with radioiodine. Ann Intern Med 1994, 121(10):757-762.
8. Baczyk M., Junik R., Ziemnicka K., Sowinski J. Iodine prophylaxis intensification. Influence on radioiodine uptake and activity of 131I used in the treatment of hyperthyroid patients with Graves' disease. Nuklearmedizin 2005, 44(5):197-199.
9. Vej-Hansen A., Nygaard B. [Iodine uptake and the effect of radioiodine treatment--status after the addition of iodine to salt]. Ugeskr Laeger 2005, 167(39):3684-3687.
10. Huysmans D.A., Nieuwlaat W.A., Erdtsieck R.J., et al. Administration of a single low dose of recombinant human thyrotropin significantly enhances thyroid radioiodide uptake in non-toxic nodular goiter. J Clin Endocrinol Metab 2000, 85(10):3592-3596.
11. Braverman L., Kloos R.T., Law B., Kipnes M., Dionne M., Magner J. Evaluation of various doses of recombinant human thyrotropin in patients with multinodular goiters. Endocr Pract 2008, 14(7):832-839.
12. Fast S., Nielsen V.E., Grupe P., Bonnema S.J., Hegedus L. Optimizing 131I uptake after rh-TSH stimulation in patients with non-toxic multinodular goiter: evidence from a prospective, randomized, double-blind study. J Nucl Med 2009, 50(5):732-737.
13. Fast S., Nielsen V.E., Bonnema S.J., Hegedus L. Dose-dependent acute effects of recombinant human TSH (rh-TSH) on thyroid size and function: comparison of 0. 1, 0. 3 and 0. 9mg of rh-TSH. Clin Endocrinol (Oxf) 2010, 72(3):411-416.
14. Nieuwlaat W.A., Huysmans D.A., van den Bosch H.C., et al. Pretreatment with a single, low dose of recombinant human thyrotropin allows dose reduction of radioiodine therapy in patients with nodular goiter. J Clin Endocrinol Metab 2003, 88(7):3121-3129.
15. Fast S., Hegedus L., Grupe P., et al. Recombinant human thyrotropin-stimulated radioiodine therapy of nodular goiter allows major reduction of the radiation burden with retained efficacy. J Clin Endocrinol Metab 2010, 95(8):3719-3725.
16. Albino CC, Graf H, Paz-Filho G, et al. Radioiodine plus recombinant human thyrotropin do not cause acute airway compression and are effective in reducing multinodular goiter. Braz J Med Biol Res 2010.
17. Albino C.C., Mesa C.O., Olandoski M., et al. Recombinant human thyrotropin as adjuvant in the treatment of multinodular goiters with radioiodine. J Clin Endocrinol Metab 2005, 90(5):2775-2780.
18. Giusti M., Caputo M., Calamia I., et al. Long-term outcome of low-activity radioiodine administration preceded by adjuvant recombinant human TSH pretreatment in elderly subjects with multinodular goiter. Thyroid Res 2009, 2(1):6.
19. Resende M., Corbo R., Vaisman M. The effect of recombinant human TSH on 123I thyroid uptake after intravenous iodide contrast agent. Nucl Med Commun 2010, 31(4):315-319.
20. Nielsen V.E., Bonnema S.J., Boel-Jorgensen H., Veje A., Hegedus L. Recombinant human thyrotropin markedly changes the 131I kinetics during 131I therapy of patients with nodular goiter: an evaluation by a randomized double-blinded trial. J Clin Endocrinol Metab 2005, 90(1):79-83.
21. Nieuwlaat W.A., Hermus A.R., Ross H.A., et al. Dosimetry of radioiodine therapy in patients with nodular goiter after pretreatment with a single, low dose of recombinant human thyroid-stimulating hormone. J Nucl Med 2004, 45(4):626-633.
22. Khandani A., Schicha H. [Two-step radioiodine therapy in benign thyroid diseases during a single hospital visit--observations on 100 patients]. Nuklearmedizin 1999, 38(5):140-143.
23. Bonnema SJ, Fast S, Nielsen VE, et al. Serum thyroxine and age - rather than thyroid volume and serum. J Endocrinol Invest 2010.
24. Nieuwlaat W.A., Hermus A.R., Sivro-Prndelj F., Corstens F.H., Huysmans D.A. Pretreatment with recombinant human TSH changes the regional distribution of radioiodine on thyroid scintigrams of nodular goiters. J Clin Endocrinol Metab 2001, 86(11):5330-5336.
25. Bonnema S.J., Nielsen V.E., Boel-Jorgensen H., et al. Improvement of goiter volume reduction after 0.3mg recombinant human thyrotropin-stimulated radioiodine therapy in patients with a very large goiter: a double-blinded, randomized trial. J Clin Endocrinol Metab 2007, 92(9):3424-3428.
26. Nielsen V.E., Bonnema S.J., Boel-Jorgensen H., Grupe P., Hegedus L. Stimulation with 0.3-mg recombinant human thyrotropin prior to iodine 131 therapy to improve the size reduction of benign non-toxic nodular goiter: a prospective randomized double-blind trial. Arch Intern Med 2006, 166(14):1476-1482.
27. Huysmans D.A., Buijs W.C., van de Ven M.T., et al. Dosimetry and risk estimates of radioiodine therapy for large, multinodular goiters. J Nucl Med 1996, 37(12):2072-2079.
28. Cubas E.R., Paz-Filho G.J., Olandoski M., et al. Recombinant human TSH increases the efficacy of a fixed activity of radioiodine for treatment of multinodular goitre. Int J Clin Pract 2009, 63(4):583-590.
29. Giusti M., Cappi C., Santaniello B., et al. Safety and efficacy of administering 0.2mg of recombinant human TSH for two consecutive days as an adjuvant to therapy with low radioiodine doses in elderly out-patients with large non-toxic multinodular goiter. Minerva Endocrinol 2006, 31(3):191-209.
30. Graf H, Fast S, Pacini F, et al. Modified-release recombinant human TSH (MRrh-TSH) augments the effect of 131I therapy in benign multinodular goiter. Results from a multicenter international, randomized, placebo-controlled study. J Clin Endocrinol Metab 2010 (in press).
31. Silva M.N., Rubio I.G., Romao R., et al. Administration of a single dose of recombinant human thyrotrophin enhances the efficacy of radioiodine treatment of large compressive multinodular goitres. Clin Endocrinol (Oxf) 2004, 60(3):300-308.
32. Gittoes N.J., Miller M.R., Daykin J., Sheppard M.C., Franklyn J.A. Upper airways obstruction in 153 consecutive patients presenting with thyroid enlargement. Br Med J 1996, 312(7029):484.
33. Bonnema S.J., Nielsen V.E., Boel-Jorgensen H., et al. Recombinant human thyrotropin-stimulated radioiodine therapy of large nodular goiters facilitates tracheal decompression and improves inspiration. J Clin Endocrinol Metab 2008, 93(10):3981-3984.
34. Hegedus L., Bonnema S.J., Bennedbaek F.N. Management of simple nodular goiter: current status and future perspectives. Endocr Rev 2003, 24(1):102-132.
35. Magner J. Problems associated with the use of thyrogen in patients with a thyroid gland. N Engl J Med 2008, 359(16):1738-1739.
36. Lawrence J.E., Emerson C.H., Sullaway S.L., Braverman L.E. The effect of recombinant human tsh on the thyroid (123)i uptake in iodide treated normal subjects. J Clin Endocrinol Metab 2001, 86(1):437-440.
37. Pena S., Arum S., Cross M., et al. 123I thyroid uptake and thyroid size at 24, 48, and 72hours after the administration of recombinant human thyroid-stimulating hormone to normal volunteers. J Clin Endocrinol Metab 2006, 91(2):506-510.
38. Torres M.S., Ramirez L., Simkin P.H., Braverman L.E., Emerson C.H. Effect of various doses of recombinant human thyrotropin on the thyroid radioactive iodine uptake and serum levels of thyroid hormones and thyroglobulin in normal subjects. J Clin Endocrinol Metab 2001, 86(4):1660-1664.
39. Barca M.F., Gruppi C., Oliveira M.T., et al. Cardiovascular assessment of hyperthyroid patients with multinodular goiter before and after radioiodine treatment preceded by stimulation with recombinant human TSH. Endocrine 2007, 32(2):175-181.
40. Nygaard B., Faber J., Hegedus L. Acute changes in thyroid volume and function following 131I therapy of multinodular goitre. Clin Endocrinol (Oxf) 1994, 41(6):715-718.
41. Romao R., Rubio I.G., Tomimori E.K., Camargo R.Y., Knobel M., Medeiros-Neto G. High prevalence of side effects after recombinant human thyrotropin-stimulated radioiodine treatment with 30 mCi in patients with multinodular goiter and subclinical/clinical hyperthyroidism. Thyroid 2009, 19(9):945-951.
42. Nielsen V.E., Bonnema S.J., Hegedus L. Effects of 0.9mg recombinant human thyrotropin on thyroid size and function in normal subjects: a randomized, double-blind, crossover trial. J Clin Endocrinol Metab 2004, 89(5):2242-2247.
43. Nielsen V.E., Bonnema S.J., Hegedus L. Transient goiter enlargement after administration of 0.3mg of recombinant human thyrotropin in patients with benign non-toxic nodular goiter: a randomized, double-blind, crossover trial. J Clin Endocrinol Metab 2006, 91(4):1317-1322.
44. Cardia M.S., Rubio I.G., Medeiros-Neto G. Prolonged follow-up of multinodular goitre patients treated with radioiodine preceded or not by human recombinant TSH. Clin Endocrinol (Oxf) 2006, 64(4):474.
45. Metso S., Auvinen A., Huhtala H., Salmi J., Oksala H., Jaatinen P. Increased cancer incidence after radioiodine treatment for hyperthyroidism. Cancer 2007, 109(10):1972-1979.
46. Wiersinga W.M. Thyroid hormone replacement therapy. Horm Res 2001, 56(Suppl. 1):74-81.
47. Watt T., Rasmussen A.K., Groenvold M., et al. Improving a newly developed patient-reported outcome for thyroid patients, using cognitive interviewing. Qual Life Res 2008, 17(7):1009-1017.
48. Fast S., Nielsen V.E., Bonnema S.J., Hegedus L. Time to reconsider nonsurgical therapy of benign non-toxic multinodular goitre: focus on recombinant human TSH augmented radioiodine therapy. Eur J Endocrinol 2009, 160(4):517-528.